

CE-IVD received for COVID-19 test

Genetic Signatures Limited (ASX: GSS, “**Genetic Signatures**” or the “**Company**”) is pleased to advise that it received the CE-IVD registration for its SARS-CoV-2 Detection Kit overnight. The application was submitted late last week as detailed in the Company’s announcement dated Monday 30 March 2020 and allows the kit to be marketed freely in the European Union.

John Melki, Genetic Signatures CEO, said, “*The COVID-19 pandemic is being fought on multiple fronts and our new molecular test will give healthcare workers in Europe a high throughput and accurate diagnostic solution to help combat this virus. It is a significant achievement to attain registration so quickly, and our team should be proud of what they have done*”.

As previously advised, Genetic Signatures has already shipped kits to Europe, and this will clear the way for supply contracts with new larger European customers. Negotiations are underway with potential customers in Germany, UK and Spain.

An application for TGA registration was also lodged at the same time, and this clearance is anticipated in the coming weeks.

The new SARS-CoV-2 Detection Kit can be used on Genetic Signatures highest throughput instrument, GS-1000, which has the ability to process approximately 1,500 samples in a 24-hour period in a fully staffed laboratory in batches of 188 samples per run.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki

Chief Executive Officer

john.melki@geneticsignatures.com

T: +61 (0)2 9870 7580

Peter Manley

Chief Financial Officer

peter.manley@geneticsignatures.com

Announcement authorised by Genetic Signatures’ Board of Directors

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base™**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the **EasyScreen™** brand. Genetic Signatures’ proprietary MDx **3base™** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures’ current target markets are major hospital and pathology laboratories undertaking infectious disease screening.